{"title":"重新考虑将拉达波的工作纳入荟萃分析:有效性问题及影响","authors":"Borja Somovilla Del Saz","doi":"10.1080/21645515.2024.2315711","DOIUrl":null,"url":null,"abstract":"<p><p>This is a response to Marchand & Masoud's response letter regarding my criticism \"Response to Dr. Somovilla del Saz's letter to the editor regarding \"Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-analysis of self-controlled case series studies.\"\" The response is a defense of the initial criticism to the paper regarding the validity of the inclusion of Ladapo´s paper.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10880802/pdf/","citationCount":"0","resultStr":"{\"title\":\"Reconsidering the inclusion of Ladapo's work in the meta-analysis: Validity concerns and implications.\",\"authors\":\"Borja Somovilla Del Saz\",\"doi\":\"10.1080/21645515.2024.2315711\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This is a response to Marchand & Masoud's response letter regarding my criticism \\\"Response to Dr. Somovilla del Saz's letter to the editor regarding \\\"Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-analysis of self-controlled case series studies.\\\"\\\" The response is a defense of the initial criticism to the paper regarding the validity of the inclusion of Ladapo´s paper.</p>\",\"PeriodicalId\":49067,\"journal\":{\"name\":\"Human Vaccines & Immunotherapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10880802/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Vaccines & Immunotherapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21645515.2024.2315711\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2024.2315711","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
这是对 Marchand 和 Masoud 就我的批评所写的回信的回应,"回应 Somovilla del Saz 博士写给编辑的关于 "接种 COVID-19 疫苗后的全因和心脏相关死亡风险:自我对照病例系列研究的荟萃分析""。该回复是对最初对该论文提出的关于纳入拉达波论文的有效性的批评的辩护。
Reconsidering the inclusion of Ladapo's work in the meta-analysis: Validity concerns and implications.
This is a response to Marchand & Masoud's response letter regarding my criticism "Response to Dr. Somovilla del Saz's letter to the editor regarding "Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: A meta-analysis of self-controlled case series studies."" The response is a defense of the initial criticism to the paper regarding the validity of the inclusion of Ladapo´s paper.
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.